• Loading stock data…

Humanigen Announces Target Enrollment in Phase 2/3 ACTIV-5/BET-B Trial of Lenzilumab for the Treatment of COVID-19 has Been Achieved

[#item_full_content]

Print Friendly, PDF & Email
Spread the word